Advertisement

Index by author

October 01, 1992; Volume 42,Issue 4

B

  1. Baez, M

    1. Molecular cloning, functional expression, and pharmacological characterization of a novel serotonin receptor (5-hydroxytryptamine2F) from rat stomach fundus.
      J D Kursar, D L Nelson, D B Wainscott, M L Cohen and M Baez
      Molecular Pharmacology October 1992, 42 (4) 549-557;

  2. Baird, S

    1. Mono- and diglucuronide formation from chrysene and benzo(a)pyrene phenols by 3-methylcholanthrene-inducible phenol UDP-glucuronosyltransferase (UGT1A1).
      K W Bock, H Gschaidmeier, A Seidel, S Baird and B Burchell
      Molecular Pharmacology October 1992, 42 (4) 613-618;

  3. Barredo, J

    1. Determinants of antifolate cytotoxicity: folylpolyglutamate synthetase activity during cellular proliferation and development.
      J Barredo and R G Moran
      Molecular Pharmacology October 1992, 42 (4) 687-694;

  4. Barrow, R K

    1. [3H]noscapine binding sites in brain: relationship to indoleamines and the phosphoinositide and adenylyl cyclase messenger systems.
      R J Mourey, T M Dawson, R K Barrow, A E Enna and S H Snyder
      Molecular Pharmacology October 1992, 42 (4) 619-626;

  5. Beck-Sickinger, A G

    1. Further characterization of neuropeptide Y receptor subtypes using centrally truncated analogs of neuropeptide Y: evidence for subtype-differentiating effects on affinity and intrinsic efficacy.
      M C Michel, W Gaida, A G Beck-Sickinger, H A Wieland, H Doods, H Dürr, G Jung and G Schnorrenberg
      Molecular Pharmacology October 1992, 42 (4) 642-648;

  6. Bensasson, R V

    1. Correlations between the rate constant of singlet oxygen quenching by imidazole derivatives and anti-inflammatory activity in rats.
      R V Bensasson, J Frederiksen, M Rougée, D Lexa and N Harrit
      Molecular Pharmacology October 1992, 42 (4) 718-722;

  7. Benveniste, M

    1. Effect of extracellular pH on the potency of N-methyl-D-aspartic acid receptor competitive antagonists.
      M Benveniste and M L Mayer
      Molecular Pharmacology October 1992, 42 (4) 679-686;

  8. Bidlack, J M

    1. Protein kinase C activation increases the rate and magnitude of agonist-induced delta-opioid receptor down-regulation in NG108-15 cells.
      S Gucker and J M Bidlack
      Molecular Pharmacology October 1992, 42 (4) 656-665;

  9. Bock, K W

    1. Mono- and diglucuronide formation from chrysene and benzo(a)pyrene phenols by 3-methylcholanthrene-inducible phenol UDP-glucuronosyltransferase (UGT1A1).
      K W Bock, H Gschaidmeier, A Seidel, S Baird and B Burchell
      Molecular Pharmacology October 1992, 42 (4) 613-618;

  10. Borden, L A

    1. Cloning and expression of a high affinity taurine transporter from rat brain.
      K E Smith, L A Borden, C H Wang, P R Hartig, T A Branchek and R L Weinshank
      Molecular Pharmacology October 1992, 42 (4) 563-569;

  11. Borgono, C

    1. Hypersensitivity to acetaldehyde-protein adducts.
      Y Israel, A MacDonald, O Niemelä, D Zamel, E Shami, M Zywulko, F Klajner and C Borgono
      Molecular Pharmacology October 1992, 42 (4) 711-717;

  12. Branchek, T A

    1. Cloning and expression of a high affinity taurine transporter from rat brain.
      K E Smith, L A Borden, C H Wang, P R Hartig, T A Branchek and R L Weinshank
      Molecular Pharmacology October 1992, 42 (4) 563-569;

  13. Burchell, B

    1. Mono- and diglucuronide formation from chrysene and benzo(a)pyrene phenols by 3-methylcholanthrene-inducible phenol UDP-glucuronosyltransferase (UGT1A1).
      K W Bock, H Gschaidmeier, A Seidel, S Baird and B Burchell
      Molecular Pharmacology October 1992, 42 (4) 613-618;

  14. Butler, R

    1. Equilibrium and kinetic studies of the interactions of salmeterol with membrane bilayers.
      D G Rhodes, R Newton, R Butler and L Herbette
      Molecular Pharmacology October 1992, 42 (4) 596-602;

C

  1. Catterall, W A

    1. Class I and IV antiarrhythmic drugs and cytosolic calcium regulate mRNA encoding the sodium channel alpha subunit in rat cardiac muscle.
      H J Duff, J Offord, J West and W A Catterall
      Molecular Pharmacology October 1992, 42 (4) 570-574;

  2. Charra, M

    1. Stimulation of topoisomerase II-mediated DNA cleavage by ellipticine derivatives: structure-activity relationship.
      P Fossé, B René, M Charra, C Paoletti and J M Saucier
      Molecular Pharmacology October 1992, 42 (4) 590-595;

  3. Cho, A K

    1. Regiochemical differences in cytochrome P450 isozymes responsible for the oxidation of methylenedioxyphenyl groups by rabbit liver.
      Y Kumagai, L Y Lin, R M Philpot, H Yamada, K Oguri, H Yoshimura and A K Cho
      Molecular Pharmacology October 1992, 42 (4) 695-702;

  4. Choudhary, M S

    1. Identification of receptor domains that modify ligand binding to 5-hydroxytryptamine2 and 5-hydroxytryptamine1c serotonin receptors.
      M S Choudhary, S Craigo and B L Roth
      Molecular Pharmacology October 1992, 42 (4) 627-633;

  5. Clarke, S D

    1. Adipocyte fatty acid-binding protein: regulation of gene expression in vivo and in vitro by an insulin-sensitizing agent.
      R F Kletzien, L A Foellmi, P K Harris, B M Wyse and S D Clarke
      Molecular Pharmacology October 1992, 42 (4) 558-562;

  6. Cohen, M L

    1. Molecular cloning, functional expression, and pharmacological characterization of a novel serotonin receptor (5-hydroxytryptamine2F) from rat stomach fundus.
      J D Kursar, D L Nelson, D B Wainscott, M L Cohen and M Baez
      Molecular Pharmacology October 1992, 42 (4) 549-557;

  7. Craigo, S

    1. Identification of receptor domains that modify ligand binding to 5-hydroxytryptamine2 and 5-hydroxytryptamine1c serotonin receptors.
      M S Choudhary, S Craigo and B L Roth
      Molecular Pharmacology October 1992, 42 (4) 627-633;

D

  1. Dawson, T M

    1. [3H]noscapine binding sites in brain: relationship to indoleamines and the phosphoinositide and adenylyl cyclase messenger systems.
      R J Mourey, T M Dawson, R K Barrow, A E Enna and S H Snyder
      Molecular Pharmacology October 1992, 42 (4) 619-626;

  2. Denison, M S

    1. In vitro transformation of the human Ah receptor and its binding to a dioxin response element.
      P A Harper, J V Giannone, A B Okey and M S Denison
      Molecular Pharmacology October 1992, 42 (4) 603-612;

  3. Doods, H

    1. Further characterization of neuropeptide Y receptor subtypes using centrally truncated analogs of neuropeptide Y: evidence for subtype-differentiating effects on affinity and intrinsic efficacy.
      M C Michel, W Gaida, A G Beck-Sickinger, H A Wieland, H Doods, H Dürr, G Jung and G Schnorrenberg
      Molecular Pharmacology October 1992, 42 (4) 642-648;

  4. Drummond, A H

    1. Chronic lithium treatment inhibits basal and agonist-stimulated responses in rat cerebral cortex and GH3 pituitary cells.
      M A Varney, P P Godfrey, A H Drummond and S P Watson
      Molecular Pharmacology October 1992, 42 (4) 671-678;

  5. Duff, H J

    1. Class I and IV antiarrhythmic drugs and cytosolic calcium regulate mRNA encoding the sodium channel alpha subunit in rat cardiac muscle.
      H J Duff, J Offord, J West and W A Catterall
      Molecular Pharmacology October 1992, 42 (4) 570-574;

  6. Dürr, H

    1. Further characterization of neuropeptide Y receptor subtypes using centrally truncated analogs of neuropeptide Y: evidence for subtype-differentiating effects on affinity and intrinsic efficacy.
      M C Michel, W Gaida, A G Beck-Sickinger, H A Wieland, H Doods, H Dürr, G Jung and G Schnorrenberg
      Molecular Pharmacology October 1992, 42 (4) 642-648;

E

  1. Ellis, J

    1. Two allosteric modulators interact at a common site on cardiac muscarinic receptors.
      J Ellis and M Seidenberg
      Molecular Pharmacology October 1992, 42 (4) 638-641;

  2. Enna, A E

    1. [3H]noscapine binding sites in brain: relationship to indoleamines and the phosphoinositide and adenylyl cyclase messenger systems.
      R J Mourey, T M Dawson, R K Barrow, A E Enna and S H Snyder
      Molecular Pharmacology October 1992, 42 (4) 619-626;

F

  1. Farber, J L

    1. Cellular pool of transient ferric iron, chelatable by deferoxamine and distinct from ferritin, that is involved in oxidative cell injury.
      R J Rothman, A Serroni and J L Farber
      Molecular Pharmacology October 1992, 42 (4) 703-710;

  2. Foellmi, L A

    1. Adipocyte fatty acid-binding protein: regulation of gene expression in vivo and in vitro by an insulin-sensitizing agent.
      R F Kletzien, L A Foellmi, P K Harris, B M Wyse and S D Clarke
      Molecular Pharmacology October 1992, 42 (4) 558-562;

  3. Fossé, P

    1. Stimulation of topoisomerase II-mediated DNA cleavage by ellipticine derivatives: structure-activity relationship.
      P Fossé, B René, M Charra, C Paoletti and J M Saucier
      Molecular Pharmacology October 1992, 42 (4) 590-595;

  4. Fraeyman, N

    1. Influence of age on the beta 1- and beta 2-adrenergic receptors in rat liver.
      A Van Ermen, E Van de Velde, P Vanscheeuwijck and N Fraeyman
      Molecular Pharmacology October 1992, 42 (4) 649-655;

  5. Frederiksen, J

    1. Correlations between the rate constant of singlet oxygen quenching by imidazole derivatives and anti-inflammatory activity in rats.
      R V Bensasson, J Frederiksen, M Rougée, D Lexa and N Harrit
      Molecular Pharmacology October 1992, 42 (4) 718-722;

G

  1. Gaida, W

    1. Further characterization of neuropeptide Y receptor subtypes using centrally truncated analogs of neuropeptide Y: evidence for subtype-differentiating effects on affinity and intrinsic efficacy.
      M C Michel, W Gaida, A G Beck-Sickinger, H A Wieland, H Doods, H Dürr, G Jung and G Schnorrenberg
      Molecular Pharmacology October 1992, 42 (4) 642-648;

  2. Giannone, J V

    1. In vitro transformation of the human Ah receptor and its binding to a dioxin response element.
      P A Harper, J V Giannone, A B Okey and M S Denison
      Molecular Pharmacology October 1992, 42 (4) 603-612;

  3. Godfrey, P P

    1. Chronic lithium treatment inhibits basal and agonist-stimulated responses in rat cerebral cortex and GH3 pituitary cells.
      M A Varney, P P Godfrey, A H Drummond and S P Watson
      Molecular Pharmacology October 1992, 42 (4) 671-678;

  4. Gschaidmeier, H

    1. Mono- and diglucuronide formation from chrysene and benzo(a)pyrene phenols by 3-methylcholanthrene-inducible phenol UDP-glucuronosyltransferase (UGT1A1).
      K W Bock, H Gschaidmeier, A Seidel, S Baird and B Burchell
      Molecular Pharmacology October 1992, 42 (4) 613-618;

  5. Gucker, S

    1. Protein kinase C activation increases the rate and magnitude of agonist-induced delta-opioid receptor down-regulation in NG108-15 cells.
      S Gucker and J M Bidlack
      Molecular Pharmacology October 1992, 42 (4) 656-665;

H

  1. Hanna, P M

    1. In vivo evidence of hydroxyl radical formation after acute copper and ascorbic acid intake: electron spin resonance spin-trapping investigation.
      M B Kadiiska, P M Hanna, L Hernandez and R P Mason
      Molecular Pharmacology October 1992, 42 (4) 723-729;

  2. Harper, P A

    1. In vitro transformation of the human Ah receptor and its binding to a dioxin response element.
      P A Harper, J V Giannone, A B Okey and M S Denison
      Molecular Pharmacology October 1992, 42 (4) 603-612;

  3. Harris, P K

    1. Adipocyte fatty acid-binding protein: regulation of gene expression in vivo and in vitro by an insulin-sensitizing agent.
      R F Kletzien, L A Foellmi, P K Harris, B M Wyse and S D Clarke
      Molecular Pharmacology October 1992, 42 (4) 558-562;

  4. Harrit, N

    1. Correlations between the rate constant of singlet oxygen quenching by imidazole derivatives and anti-inflammatory activity in rats.
      R V Bensasson, J Frederiksen, M Rougée, D Lexa and N Harrit
      Molecular Pharmacology October 1992, 42 (4) 718-722;

  5. Hartig, P R

    1. Cloning and expression of a high affinity taurine transporter from rat brain.
      K E Smith, L A Borden, C H Wang, P R Hartig, T A Branchek and R L Weinshank
      Molecular Pharmacology October 1992, 42 (4) 563-569;

  6. Haynes, A R

    1. Modulation of platelet-derived growth factor B mRNA abundance in macrophages by colchicine and dibutyryl-cAMP.
      A Wangoo, A R Haynes, S P Sutcliffe, M Sorooshian and R J Shaw
      Molecular Pharmacology October 1992, 42 (4) 584-589;

  7. Herbette, L

    1. Equilibrium and kinetic studies of the interactions of salmeterol with membrane bilayers.
      D G Rhodes, R Newton, R Butler and L Herbette
      Molecular Pharmacology October 1992, 42 (4) 596-602;

  8. Hernandez, L

    1. In vivo evidence of hydroxyl radical formation after acute copper and ascorbic acid intake: electron spin resonance spin-trapping investigation.
      M B Kadiiska, P M Hanna, L Hernandez and R P Mason
      Molecular Pharmacology October 1992, 42 (4) 723-729;

I

  1. Israel, Y

    1. Hypersensitivity to acetaldehyde-protein adducts.
      Y Israel, A MacDonald, O Niemelä, D Zamel, E Shami, M Zywulko, F Klajner and C Borgono
      Molecular Pharmacology October 1992, 42 (4) 711-717;

J

  1. Jung, G

    1. Further characterization of neuropeptide Y receptor subtypes using centrally truncated analogs of neuropeptide Y: evidence for subtype-differentiating effects on affinity and intrinsic efficacy.
      M C Michel, W Gaida, A G Beck-Sickinger, H A Wieland, H Doods, H Dürr, G Jung and G Schnorrenberg
      Molecular Pharmacology October 1992, 42 (4) 642-648;

K

  1. Kadiiska, M B

    1. In vivo evidence of hydroxyl radical formation after acute copper and ascorbic acid intake: electron spin resonance spin-trapping investigation.
      M B Kadiiska, P M Hanna, L Hernandez and R P Mason
      Molecular Pharmacology October 1992, 42 (4) 723-729;

  2. Klajner, F

    1. Hypersensitivity to acetaldehyde-protein adducts.
      Y Israel, A MacDonald, O Niemelä, D Zamel, E Shami, M Zywulko, F Klajner and C Borgono
      Molecular Pharmacology October 1992, 42 (4) 711-717;

  3. Kletzien, R F

    1. Adipocyte fatty acid-binding protein: regulation of gene expression in vivo and in vitro by an insulin-sensitizing agent.
      R F Kletzien, L A Foellmi, P K Harris, B M Wyse and S D Clarke
      Molecular Pharmacology October 1992, 42 (4) 558-562;

  4. Kumagai, Y

    1. Regiochemical differences in cytochrome P450 isozymes responsible for the oxidation of methylenedioxyphenyl groups by rabbit liver.
      Y Kumagai, L Y Lin, R M Philpot, H Yamada, K Oguri, H Yoshimura and A K Cho
      Molecular Pharmacology October 1992, 42 (4) 695-702;

  5. Kunze, D L

    1. Characterization of the effects of a new Ca2+ channel activator, FPL 64176, in GH3 cells.
      D L Kunze and D Rampe
      Molecular Pharmacology October 1992, 42 (4) 666-670;

  6. Kursar, J D

    1. Molecular cloning, functional expression, and pharmacological characterization of a novel serotonin receptor (5-hydroxytryptamine2F) from rat stomach fundus.
      J D Kursar, D L Nelson, D B Wainscott, M L Cohen and M Baez
      Molecular Pharmacology October 1992, 42 (4) 549-557;

L

  1. Leslie, F M

    1. kappa-Opioid inhibition of [3H]dopamine release from rat ventral mesencephalic dissociated cell cultures.
      J A Smith, S E Loughlin and F M Leslie
      Molecular Pharmacology October 1992, 42 (4) 575-583;

  2. Lexa, D

    1. Correlations between the rate constant of singlet oxygen quenching by imidazole derivatives and anti-inflammatory activity in rats.
      R V Bensasson, J Frederiksen, M Rougée, D Lexa and N Harrit
      Molecular Pharmacology October 1992, 42 (4) 718-722;

  3. Liggett, S B

    1. Functional properties of the rat and human beta 3-adrenergic receptors: differential agonist activation of recombinant receptors in Chinese hamster ovary cells.
      S B Liggett
      Molecular Pharmacology October 1992, 42 (4) 634-637;

  4. Lin, L Y

    1. Regiochemical differences in cytochrome P450 isozymes responsible for the oxidation of methylenedioxyphenyl groups by rabbit liver.
      Y Kumagai, L Y Lin, R M Philpot, H Yamada, K Oguri, H Yoshimura and A K Cho
      Molecular Pharmacology October 1992, 42 (4) 695-702;

  5. Loughlin, S E

    1. kappa-Opioid inhibition of [3H]dopamine release from rat ventral mesencephalic dissociated cell cultures.
      J A Smith, S E Loughlin and F M Leslie
      Molecular Pharmacology October 1992, 42 (4) 575-583;

M

  1. MacDonald, A

    1. Hypersensitivity to acetaldehyde-protein adducts.
      Y Israel, A MacDonald, O Niemelä, D Zamel, E Shami, M Zywulko, F Klajner and C Borgono
      Molecular Pharmacology October 1992, 42 (4) 711-717;

  2. Mason, R P

    1. In vivo evidence of hydroxyl radical formation after acute copper and ascorbic acid intake: electron spin resonance spin-trapping investigation.
      M B Kadiiska, P M Hanna, L Hernandez and R P Mason
      Molecular Pharmacology October 1992, 42 (4) 723-729;

  3. Mayer, M L

    1. Effect of extracellular pH on the potency of N-methyl-D-aspartic acid receptor competitive antagonists.
      M Benveniste and M L Mayer
      Molecular Pharmacology October 1992, 42 (4) 679-686;

  4. Michel, M C

    1. Further characterization of neuropeptide Y receptor subtypes using centrally truncated analogs of neuropeptide Y: evidence for subtype-differentiating effects on affinity and intrinsic efficacy.
      M C Michel, W Gaida, A G Beck-Sickinger, H A Wieland, H Doods, H Dürr, G Jung and G Schnorrenberg
      Molecular Pharmacology October 1992, 42 (4) 642-648;

  5. Moran, R G

    1. Determinants of antifolate cytotoxicity: folylpolyglutamate synthetase activity during cellular proliferation and development.
      J Barredo and R G Moran
      Molecular Pharmacology October 1992, 42 (4) 687-694;

  6. Mourey, R J

    1. [3H]noscapine binding sites in brain: relationship to indoleamines and the phosphoinositide and adenylyl cyclase messenger systems.
      R J Mourey, T M Dawson, R K Barrow, A E Enna and S H Snyder
      Molecular Pharmacology October 1992, 42 (4) 619-626;

N

  1. Nelson, D L

    1. Molecular cloning, functional expression, and pharmacological characterization of a novel serotonin receptor (5-hydroxytryptamine2F) from rat stomach fundus.
      J D Kursar, D L Nelson, D B Wainscott, M L Cohen and M Baez
      Molecular Pharmacology October 1992, 42 (4) 549-557;

  2. Newton, R

    1. Equilibrium and kinetic studies of the interactions of salmeterol with membrane bilayers.
      D G Rhodes, R Newton, R Butler and L Herbette
      Molecular Pharmacology October 1992, 42 (4) 596-602;

  3. Niemelä, O

    1. Hypersensitivity to acetaldehyde-protein adducts.
      Y Israel, A MacDonald, O Niemelä, D Zamel, E Shami, M Zywulko, F Klajner and C Borgono
      Molecular Pharmacology October 1992, 42 (4) 711-717;

O

  1. Offord, J

    1. Class I and IV antiarrhythmic drugs and cytosolic calcium regulate mRNA encoding the sodium channel alpha subunit in rat cardiac muscle.
      H J Duff, J Offord, J West and W A Catterall
      Molecular Pharmacology October 1992, 42 (4) 570-574;

  2. Oguri, K

    1. Regiochemical differences in cytochrome P450 isozymes responsible for the oxidation of methylenedioxyphenyl groups by rabbit liver.
      Y Kumagai, L Y Lin, R M Philpot, H Yamada, K Oguri, H Yoshimura and A K Cho
      Molecular Pharmacology October 1992, 42 (4) 695-702;

  3. Okey, A B

    1. In vitro transformation of the human Ah receptor and its binding to a dioxin response element.
      P A Harper, J V Giannone, A B Okey and M S Denison
      Molecular Pharmacology October 1992, 42 (4) 603-612;

P

  1. Paoletti, C

    1. Stimulation of topoisomerase II-mediated DNA cleavage by ellipticine derivatives: structure-activity relationship.
      P Fossé, B René, M Charra, C Paoletti and J M Saucier
      Molecular Pharmacology October 1992, 42 (4) 590-595;

  2. Philpot, R M

    1. Regiochemical differences in cytochrome P450 isozymes responsible for the oxidation of methylenedioxyphenyl groups by rabbit liver.
      Y Kumagai, L Y Lin, R M Philpot, H Yamada, K Oguri, H Yoshimura and A K Cho
      Molecular Pharmacology October 1992, 42 (4) 695-702;

R

  1. Rampe, D

    1. Characterization of the effects of a new Ca2+ channel activator, FPL 64176, in GH3 cells.
      D L Kunze and D Rampe
      Molecular Pharmacology October 1992, 42 (4) 666-670;

  2. René, B

    1. Stimulation of topoisomerase II-mediated DNA cleavage by ellipticine derivatives: structure-activity relationship.
      P Fossé, B René, M Charra, C Paoletti and J M Saucier
      Molecular Pharmacology October 1992, 42 (4) 590-595;

  3. Rhodes, D G

    1. Equilibrium and kinetic studies of the interactions of salmeterol with membrane bilayers.
      D G Rhodes, R Newton, R Butler and L Herbette
      Molecular Pharmacology October 1992, 42 (4) 596-602;

  4. Roth, B L

    1. Identification of receptor domains that modify ligand binding to 5-hydroxytryptamine2 and 5-hydroxytryptamine1c serotonin receptors.
      M S Choudhary, S Craigo and B L Roth
      Molecular Pharmacology October 1992, 42 (4) 627-633;

  5. Rothman, R J

    1. Cellular pool of transient ferric iron, chelatable by deferoxamine and distinct from ferritin, that is involved in oxidative cell injury.
      R J Rothman, A Serroni and J L Farber
      Molecular Pharmacology October 1992, 42 (4) 703-710;

  6. Rougée, M

    1. Correlations between the rate constant of singlet oxygen quenching by imidazole derivatives and anti-inflammatory activity in rats.
      R V Bensasson, J Frederiksen, M Rougée, D Lexa and N Harrit
      Molecular Pharmacology October 1992, 42 (4) 718-722;

S

  1. Saucier, J M

    1. Stimulation of topoisomerase II-mediated DNA cleavage by ellipticine derivatives: structure-activity relationship.
      P Fossé, B René, M Charra, C Paoletti and J M Saucier
      Molecular Pharmacology October 1992, 42 (4) 590-595;

  2. Schnorrenberg, G

    1. Further characterization of neuropeptide Y receptor subtypes using centrally truncated analogs of neuropeptide Y: evidence for subtype-differentiating effects on affinity and intrinsic efficacy.
      M C Michel, W Gaida, A G Beck-Sickinger, H A Wieland, H Doods, H Dürr, G Jung and G Schnorrenberg
      Molecular Pharmacology October 1992, 42 (4) 642-648;

  3. Seidel, A

    1. Mono- and diglucuronide formation from chrysene and benzo(a)pyrene phenols by 3-methylcholanthrene-inducible phenol UDP-glucuronosyltransferase (UGT1A1).
      K W Bock, H Gschaidmeier, A Seidel, S Baird and B Burchell
      Molecular Pharmacology October 1992, 42 (4) 613-618;

  4. Seidenberg, M

    1. Two allosteric modulators interact at a common site on cardiac muscarinic receptors.
      J Ellis and M Seidenberg
      Molecular Pharmacology October 1992, 42 (4) 638-641;

  5. Serroni, A

    1. Cellular pool of transient ferric iron, chelatable by deferoxamine and distinct from ferritin, that is involved in oxidative cell injury.
      R J Rothman, A Serroni and J L Farber
      Molecular Pharmacology October 1992, 42 (4) 703-710;

  6. Shami, E

    1. Hypersensitivity to acetaldehyde-protein adducts.
      Y Israel, A MacDonald, O Niemelä, D Zamel, E Shami, M Zywulko, F Klajner and C Borgono
      Molecular Pharmacology October 1992, 42 (4) 711-717;

  7. Shaw, R J

    1. Modulation of platelet-derived growth factor B mRNA abundance in macrophages by colchicine and dibutyryl-cAMP.
      A Wangoo, A R Haynes, S P Sutcliffe, M Sorooshian and R J Shaw
      Molecular Pharmacology October 1992, 42 (4) 584-589;

  8. Smith, J A

    1. kappa-Opioid inhibition of [3H]dopamine release from rat ventral mesencephalic dissociated cell cultures.
      J A Smith, S E Loughlin and F M Leslie
      Molecular Pharmacology October 1992, 42 (4) 575-583;

  9. Smith, K E

    1. Cloning and expression of a high affinity taurine transporter from rat brain.
      K E Smith, L A Borden, C H Wang, P R Hartig, T A Branchek and R L Weinshank
      Molecular Pharmacology October 1992, 42 (4) 563-569;

  10. Snyder, S H

    1. [3H]noscapine binding sites in brain: relationship to indoleamines and the phosphoinositide and adenylyl cyclase messenger systems.
      R J Mourey, T M Dawson, R K Barrow, A E Enna and S H Snyder
      Molecular Pharmacology October 1992, 42 (4) 619-626;

  11. Sorooshian, M

    1. Modulation of platelet-derived growth factor B mRNA abundance in macrophages by colchicine and dibutyryl-cAMP.
      A Wangoo, A R Haynes, S P Sutcliffe, M Sorooshian and R J Shaw
      Molecular Pharmacology October 1992, 42 (4) 584-589;

  12. Sutcliffe, S P

    1. Modulation of platelet-derived growth factor B mRNA abundance in macrophages by colchicine and dibutyryl-cAMP.
      A Wangoo, A R Haynes, S P Sutcliffe, M Sorooshian and R J Shaw
      Molecular Pharmacology October 1992, 42 (4) 584-589;

V

  1. Van de Velde, E

    1. Influence of age on the beta 1- and beta 2-adrenergic receptors in rat liver.
      A Van Ermen, E Van de Velde, P Vanscheeuwijck and N Fraeyman
      Molecular Pharmacology October 1992, 42 (4) 649-655;

  2. Van Ermen, A

    1. Influence of age on the beta 1- and beta 2-adrenergic receptors in rat liver.
      A Van Ermen, E Van de Velde, P Vanscheeuwijck and N Fraeyman
      Molecular Pharmacology October 1992, 42 (4) 649-655;

  3. Vanscheeuwijck, P

    1. Influence of age on the beta 1- and beta 2-adrenergic receptors in rat liver.
      A Van Ermen, E Van de Velde, P Vanscheeuwijck and N Fraeyman
      Molecular Pharmacology October 1992, 42 (4) 649-655;

  4. Varney, M A

    1. Chronic lithium treatment inhibits basal and agonist-stimulated responses in rat cerebral cortex and GH3 pituitary cells.
      M A Varney, P P Godfrey, A H Drummond and S P Watson
      Molecular Pharmacology October 1992, 42 (4) 671-678;

W

  1. Wainscott, D B

    1. Molecular cloning, functional expression, and pharmacological characterization of a novel serotonin receptor (5-hydroxytryptamine2F) from rat stomach fundus.
      J D Kursar, D L Nelson, D B Wainscott, M L Cohen and M Baez
      Molecular Pharmacology October 1992, 42 (4) 549-557;

  2. Wang, C H

    1. Cloning and expression of a high affinity taurine transporter from rat brain.
      K E Smith, L A Borden, C H Wang, P R Hartig, T A Branchek and R L Weinshank
      Molecular Pharmacology October 1992, 42 (4) 563-569;

  3. Wangoo, A

    1. Modulation of platelet-derived growth factor B mRNA abundance in macrophages by colchicine and dibutyryl-cAMP.
      A Wangoo, A R Haynes, S P Sutcliffe, M Sorooshian and R J Shaw
      Molecular Pharmacology October 1992, 42 (4) 584-589;

  4. Watson, S P

    1. Chronic lithium treatment inhibits basal and agonist-stimulated responses in rat cerebral cortex and GH3 pituitary cells.
      M A Varney, P P Godfrey, A H Drummond and S P Watson
      Molecular Pharmacology October 1992, 42 (4) 671-678;

  5. Weinshank, R L

    1. Cloning and expression of a high affinity taurine transporter from rat brain.
      K E Smith, L A Borden, C H Wang, P R Hartig, T A Branchek and R L Weinshank
      Molecular Pharmacology October 1992, 42 (4) 563-569;

  6. West, J

    1. Class I and IV antiarrhythmic drugs and cytosolic calcium regulate mRNA encoding the sodium channel alpha subunit in rat cardiac muscle.
      H J Duff, J Offord, J West and W A Catterall
      Molecular Pharmacology October 1992, 42 (4) 570-574;

  7. Wieland, H A

    1. Further characterization of neuropeptide Y receptor subtypes using centrally truncated analogs of neuropeptide Y: evidence for subtype-differentiating effects on affinity and intrinsic efficacy.
      M C Michel, W Gaida, A G Beck-Sickinger, H A Wieland, H Doods, H Dürr, G Jung and G Schnorrenberg
      Molecular Pharmacology October 1992, 42 (4) 642-648;

  8. Wyse, B M

    1. Adipocyte fatty acid-binding protein: regulation of gene expression in vivo and in vitro by an insulin-sensitizing agent.
      R F Kletzien, L A Foellmi, P K Harris, B M Wyse and S D Clarke
      Molecular Pharmacology October 1992, 42 (4) 558-562;

Y

  1. Yamada, H

    1. Regiochemical differences in cytochrome P450 isozymes responsible for the oxidation of methylenedioxyphenyl groups by rabbit liver.
      Y Kumagai, L Y Lin, R M Philpot, H Yamada, K Oguri, H Yoshimura and A K Cho
      Molecular Pharmacology October 1992, 42 (4) 695-702;

  2. Yoshimura, H

    1. Regiochemical differences in cytochrome P450 isozymes responsible for the oxidation of methylenedioxyphenyl groups by rabbit liver.
      Y Kumagai, L Y Lin, R M Philpot, H Yamada, K Oguri, H Yoshimura and A K Cho
      Molecular Pharmacology October 1992, 42 (4) 695-702;

Z

  1. Zamel, D

    1. Hypersensitivity to acetaldehyde-protein adducts.
      Y Israel, A MacDonald, O Niemelä, D Zamel, E Shami, M Zywulko, F Klajner and C Borgono
      Molecular Pharmacology October 1992, 42 (4) 711-717;

  2. Zywulko, M

    1. Hypersensitivity to acetaldehyde-protein adducts.
      Y Israel, A MacDonald, O Niemelä, D Zamel, E Shami, M Zywulko, F Klajner and C Borgono
      Molecular Pharmacology October 1992, 42 (4) 711-717;
Back to top

In this issue

Advertisement